Compare Crispr Therapeutics AG (CRSP) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Tripadvisor Inc Common Stock — how do they compare? Crispr Therapeutics AG trades at $53.51 (market cap $4.88B), while Tripadvisor Inc Common Stock trades at $8.71 (market cap $1.01B). The key difference: Crispr Therapeutics AG is far larger — about 4.8× Tripadvisor Inc Common Stock's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| CRSP | TRIP | |
|---|---|---|
Market Cap | $4.88B | $1.01B |
Volume | 2,861,747 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $16.72 |
52-Week Low | $44.34 | $8.04 |
Typical Hold Time | 77 Days | 57 Days |
Enterprise Value | $3.30B | $1.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
TripAdvisor (TRIP) trades at $8.69, up 0.7% on the day, but remains near its 52-week low of $8.27 (Defense World, 2026-09-25). The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported Q2 2026 earnings of $0.35 per share, missing the $0.375 estimate (Zacks Investment Research, 2026-08-06), while revenue trends show modest growth from $1.5B in 2022 to $1.9B in 2025. Analyst sentiment is cautious with a consensus price target of $13.58, implying significant upside potential from current levels.
The outlook for TRIP hinges on its ability to stabilize core business performance amid competitive pressures from AI-driven travel platforms. Investment opportunity lies in the discounted valuation relative to analyst targets, but risks include persistent earnings misses, declining net cash flow, and market share erosion. The completion of TheFork subsidiary sale could provide a near-term catalyst, but execution remains key for shareholder value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
